Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): C Noah Nilsson , Mads Kristian Ersbøll , Finn Gustafsson Added: 1 year ago

Heart Failure
Aldosterone Synthase Inhibitors
Author(s): Shubh K Patel , Hwee Teoh , Ahreni Saunthar , et al Added: 6 months ago

Cardiovascular Renal Metabolic
David Wheeler
Research Area(s) / Expertise:

Chronic Kidney Disease

 Job title: Professor of Kidney Medicine
David Wheeler is Professor of Kidney Medicine at University College London and Honorary Consultant Nephrologist at the Royal Free London NHS Foundation Trust.Prof Wheeler is a clinician scientist interested in the complications of chronic kidney disease (CKD), specifically those that increase the burden of cardiovascular disease and/or accelerate progression of kidney failure. He has participated… View more
Job title: PhD, RD, FHFSA, FASPEN
Dr Salvatore Carbone, PhD, RDN, MS, FHFSA, FASPEN is an Associate Professor and Program Director of the Nutrition Program at the EVMS School of Health Professions, and an Associate Professor within the EVMS Division of Endocrine and Metabolic Disorders, Strelitz Diabetes Center, Department of Internal Medicine, at the Macon & Joan Brock Virginia Health Sciences at Old Dominion University… View more
ARNI for Optimising HFrEF Management
Author(s): Massimo Iacoviello , Filippo M Sarullo , Claudio Bilato , et al Added: 7 months ago

Heart Failure
New Insights on HFpEF Treatment
Author(s): Giulio Balestrieri , Raul Limonta , Enrico Ponti , et al Added: 1 year ago

Guidelines & Statements

Heart Failure
Understanding the Role of GLP-1 RAs in the Treatment of HF
Author(s): Giovanni Battista Bonfioli , Matteo Pagnesi , Daniela Tomasoni , et al Added: 6 months ago

Cardiovascular Renal Metabolic
The Evolving Treatment Landscape for HFpEF in Cardiac Amyloidosis
Author(s): Added: 3 months ago
AHA Scientific Sessions 2025 - Dr Sarah Cuddy (Brigham and Women's Hospital, US) joins us to discuss the role of non-disease modifying treatments including SGLT2 inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, and implantable hemodynamic monitors in cardiac amyloidosis, and what this means for managing heart failure in this unique patient population.Interview… View more

Heart Failure
Heart Failure Treatment and Cardiac Amyloidosis
Author(s): Giorgia Panichella , Alberto Aimo , Vincenzo Castiglione , et al Added: 7 months ago

Heart Failure
AHA 24: The EMPEROR-Preserved Trial
Author(s): Andrew JS Coats Added: 1 year ago
AHA Conference 2024 - Discover the findings from a new study on the impact of diastolic dysfunction on the efficacy of empagliflozin in heart failure in the EMPEROR-Preserved trial.Prof Andrew Coats (Heart Research Institute, New South Wales, AU) joins us onsite at AHA Conference to discuss findings from a new analysis of diastolic dysfunction in the EMPEROR-Preserved trial (NCT03057951).EMPEROR… View more

Heart Failure